FDA Warns Against Power Morcellators For Uterine Fibroid Surgery
This article was originally published in The Gray Sheet
FDA is discouraging use of laparoscopic power morcellation as a therapy for uterine fibroids due to risk of spreading cancer tissue. The agency has instructed manufacturers to ensure that device labeling accurately displays risks; it is planning an advisory panel meeting on the topic for the summer.
You may also be interested in...
The company was sued by a Georgia woman who said the surgical tool allowed uterine cancer to spread throughout her abdomen. Terms of the settlement were not disclosed.
Anesthesiologist Amy Reed, who with her cardiologist husband Hooman Noorchasm turned her battle against uterine cancer into a crusade to abolish unsafe uses of power morcellators, died May 24 at her home in Yardley, Pa., at the age of 44.
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.